[对卵巢内分泌瘤的二诺日斯特的有效性和安全性]
1Department of Obstetrics and Gynecology, the First Clinical School of Medicine, Nanjing Medical University, Nanjing 210029, China.
Zhonghua fu chan ke za zhi
|September 23, 2024
概括
迪昂格斯特显著降低了卵巢内膜瘤 (OMA) 的体积和与子宫内膜异位症相关的疼痛. 这种治疗显示出良好的安全性,患者观察到的副作用最小.
科学领域:
- 妇科 妇科医生 妇科
- 药理学 药理学是指药理学的学科.
- 生殖医学 生殖医学
背景情况:
- 卵巢内膜瘤 (OMA) 是一种常见的妇科疾病.
- 对OMA有效和安全的治疗选择对于改善患者的生活质量至关重要.
研究的目的:
- 为了评估dienogest在减少OMA体积方面的有效性.
- 评估dienogest对子宫内膜异位症相关疼痛的影响.
- 为了监测OMA患者在dienogest治疗的安全性和副作用.
主要方法:
- 对75名OMA患者的回顾性分析,这些患者接受了二诺日斯特 (每天2毫克) 治疗.
- OMA体积和视觉模拟尺度 (VAS) 疼痛分数在治疗前后进行比较.
- 监测血液生物标志物 (CA125,CA19-9),肝/功能,凝血和乳腺健康.
主要成果:
- 在3,6个月和12个月观察到OMA体积的显著减少 (降低至77.62%).
- 在治疗期间实现了与子宫内膜异位症相关的疼痛的完全缓解 (VAS分数为0毫米).
- CA125和CA19-9水平逐渐下降;肝脏,脏或凝血功能没有显著变化.
- 没有检测到乳腺癌或癌前病变,尽管少数患者发生了乳腺结节的轻微变化.
结论:
- 迪恩奥杰斯特是一种有效的治疗方法,可以减少OMA的体积.
- 迪恩诺杰斯特有效地缓解了与子宫内膜异位症相关的疼痛.
- 迪恩诺杰斯特显示出良好的安全性,副作用很少.
相关概念视频
02:07Oogenesis
63.5K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.5K
01:27Ovarian Cycle
1.1K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.1K
01:22Hormonal Regulation of the Menstrual Cycle
315
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
315